Egetis Therapeutics

Egetis Therapeutics is an integrated pharmaceutical company executing a de-risked, late-stage orphan drug strategy. Its core achievement is the EU marketing authorization and launch in Germany for Emcitate® (tiratricol), the first-ever treatment for the ultra-rare Allan-Herndon-Dudley Syndrome (MCT8 deficiency), with a US NDA under Priority Review. The company's strategy centers on advancing this asset through global approvals and commercialization while preparing its second program, Aladote®, for pivotal studies, aiming to build a sustainable portfolio of niche therapies.

Egetis operates a specialized late-stage development and commercialization platform for orphan drugs, focusing on the clinical and regulatory advancement of known or repurposed small molecules with established mechanisms of action for niche indications.

Emcitate faces no direct therapeutic competition for MCT8 deficiency, enjoying a first-in-class monopoly. Aladote will compete against the generic standard of care (N-acetylcysteine) and must demonstrate clear clinical advantages. Egetis's broader competition is for investment and partnership within the crowded orphan drug sector.